The portfolio, which is currently marketed by Biogen and UCB, had sales of around Rs 55 crore in FY17.
Eisai expects this portfolio to grow at 10% CAGR and said it will start contributing a third to the company’s revenues in the next three years.
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morning
YOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more